<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92424">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01924754</url>
  </required_header>
  <id_info>
    <org_study_id>GINI</org_study_id>
    <nct_id>NCT01924754</nct_id>
  </id_info>
  <brief_title>Gardasil Immunogenicity With Needle-Free Injection</brief_title>
  <acronym>GINI</acronym>
  <official_title>Gardasil Immunogenicity With Needle-Free Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In collaboration with the Thai Red Cross AIDS Research Centre, the investigators are
      performing a study of 2 new HPV vaccine delivery regimens in healthy young Thai women.  The
      study will be performed in Bangkok.  The investigators will be testing the serum from these
      women at UCSF for HPV antibodies to measure the strength of their response to the vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Seroconversion Group III vs Group I</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Compare rates of seroconversion and geometric mean titers (GMTs) generated following a 3-dose series of vaccine in women given low doses of vaccine by the intradermal (ID) route with the needle-free injector (NFI) (Group III) to those women given standard doses by the intramuscular (IM) route with a needle and syringe (Group I) at 1 month, 6 months and 12 months following completion of the vaccination series.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Group II vs Group I</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Compare rates of seroconversion and GMTs generated following a 3-dose series of vaccine in women given standard doses of vaccine by the IM route with the NFI (Group II) to those women given standard doses by the IM route with a needle and syringe (Group I) at 1 month, 6 months and 12 months following completion of the vaccination series.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HPV Seroconversion</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>HPV vaccination regime-standard 3-dose needle injection IM regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <description>HPV vaccination regime-3-dose needle-free (NFI) IM injection regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <description>HPV vaccination regime - 3-dose needle-free intradermal injection regimen</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study is only for women; the study is focused on the safety and immunogenicity of the
        HPV vaccine in women.  Separate studies will be done in men if the dosing regimens in
        Groups II or III are shown to be non-inferior to the standard regimen.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thai women age 18-26 years

          -  no more than 5 lifetime partners

          -  HIV-uninfected

          -  no history of HPV vaccination

          -  judged able to complete all of the protocol visits

          -  no contraindications to vaccination with Gardasil

        Exclusion Criteria:

        -  Does not satisfy all of the inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Palefsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joel Palefsky, MD</last_name>
      <phone>415-476-1574</phone>
      <email>jpalefsky@medicine.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Joel Palefsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nittaya Phanuphak, MD</last_name>
      <email>nittaya.p@trcarc.org</email>
    </contact>
    <contact_backup>
      <last_name>Siriporn NSiriporn Nonenoy</last_name>
      <email>siriporn.n@searchthailand.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nittaya Phanuphak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>Gardasil</keyword>
  <keyword>seroconversion</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
